Alnylam, Dicerna Settle Trade Secrets Case Ahead Of Trial
With a trial looming, Dicerna Pharmaceuticals Inc. announced Friday it would shell out $15 million and close to a million shares of common stock to end Massachusetts state and federal court...To view the full article, register now.
Already a subscriber? Click here to view full article